Gary Meininger MD
Diabetes, Lipid Metabolism
Executive Vice President and Chief Medical Officer
Join to View Full Profile
300 Technology SquareSuite 700Cambridge, MA 02139
Dr. Meininger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts General HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 1999 - 2002
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1996 - 1999
New York University School of MedicineClass of 1996, MD, AOA
Certifications & Licensure
NJ State Medical License 2002 - 2025
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Publications & Presentations
PubMed
- 14 citationsKidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.Tae Won Yi, Brendan Smyth, Gian Luca Di Tanna, Clare Arnott, Kathryn Cardoza
American Journal of Kidney Diseases. 2023-07-01 - 2 citationsAcute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study.Zhong Yuan, Frank J. DeFalco, Lu Wang, Laura Hester, James Weaver
Current Medical Research and Opinion. 2020-05-14 - 31 citationsDiabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co‐transporter 2 inhibitors versus other antihyperglycemic agents: An observational ...Lu Wang, Erica A. Voss, James Weaver, Laura Hester, Zhong Yuan
Pharmacoepidemiology and Drug Safety. 2019-08-27
Journal Articles
- Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from IndiaK. M. Prasanna Kumar, Viswanathan Mohan, Bipin Sethi, Pramod Gandhi, Ganapathi Bantwal, John Xie, Gary Meininger, Rong Qiu, Indian Journal of Endocrinology and Metabolism, 4/2016
- Canagliflozin for the treatment of adults with Type 2 diabetesMeininger G, Canovatchel W, Polidori D, Rosenthal N, Diabetes Management, 2015
Press Mentions
Drug to Delay T1D Gets Tepid Endorsement by FDA AdvisorsMay 28th, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
